AEMD
What one share of Aethlon Medical holds
Surgical and Medical Instruments and Apparatus
EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer,
Aethlon Medical’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$9.13 |
|---|---|
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$9.47 |
| Cash and investments | $10.33 |
| Book value | $10.89 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2025 | — | −$85.77 | $0.00 | −$48.98 | — | $25.48 |
| 2026 | — | −$10.61 | $0.01 | −$10.39 | — | $15.56 |